Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership

VACCINEX, INC.

Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.
In MCI patients, reduced astrocyte reactivity (GFAP) and neuronal damage marker p-tau217; no effect in early dementia.
Cognitive decline slowed in MCI per iADRS and ADAS-Cog13; no benefit in early dementia group.
Company plans to pursue a development partnership to reduce operating expenses going forward.
Pepinemab was well-tolerated, consistent with prior Huntington's disease studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.